Rimonabant powder

Rimonabant powder video

Raw Rimonabant powder basic Characters

Rimonabant Background

The historical background of Rimonabant dates back to the late 1990s and early 2000s when researchers began investigating the endocannabinoid system and its potential implications in various physiological processes, including appetite regulation and energy balance.

During this period, scientists identified cannabinoid receptors in the body, known as CB1 receptors, which are predominantly found in the brain and peripheral tissues. These receptors play a role in modulating appetite, food intake, and energy expenditure.

Motivated by the growing understanding of the endocannabinoid system’s involvement in appetite control, pharmaceutical companies initiated the development of selective CB1 receptor antagonists to target obesity and related conditions.

In 1999, the French pharmaceutical company Sanofi-Synthélabo (now Sanofi) began developing a drug called Rimonabant. Rimonabant was designed to selectively block CB1 receptors, effectively inhibiting the activity of the endocannabinoid system.

Clinical trials were conducted to evaluate the efficacy and safety of Rimonabant in the management of obesity and associated metabolic disorders. The studies showed promising results, demonstrating weight loss and improvements in cardiovascular risk factors, such as cholesterol levels and insulin resistance.

Based on the positive outcomes from these trials, Rimonabant received regulatory approval in 2006 in the European Union under the trade name Acomplia. It was the first medication specifically developed for the treatment of obesity in over a decade.

However, despite its initial success, Rimonabant faced challenges and controversies. Reports of psychiatric side effects, including depression, anxiety, and suicidal ideation, emerged during post-marketing surveillance. Concerns over these adverse effects led to the withdrawal of Rimonabant from the market in several countries, including the European Union in 2008.

The withdrawal of Rimonabant highlighted the importance of carefully assessing the safety and potential psychiatric risks associated with drugs targeting the endocannabinoid system. While Rimonabant did not fulfill its original promise as an anti-obesity medication, it provided valuable insights into the complex interplay between the endocannabinoid system and metabolic regulation.

Since the withdrawal of Rimonabant, research efforts have continued to explore the therapeutic potential of targeting the endocannabinoid system, but with a greater focus on developing compounds that mitigate the psychiatric risks associated with CB1 receptor blockade.

Rimonabant Powder

Rimonabant Powder is a pharmaceutical substance that gained attention for its potential use in the medical field. It belongs to a class of drugs known as selective cannabinoid receptor antagonists. Rimonabant was initially developed as an anti-obesity medication, targeting the endocannabinoid system to help regulate appetite and weight.

The Powder form of Rimonabant allows for easy handling and dispersion during formulation processes. Rimonabant Powder is sparingly soluble in water, which means it has limited solubility in aqueous solutions. However, it can exhibit better solubility in organic solvents such as ethanol, methanol, or propylene glycol. The solubility characteristics of Rimonabant are important considerations during formulation development.

Rimonabant mechanism of action

The mechanism of action of Rimonabant involves its interaction with the endocannabinoid system in the body. Rimonabant is a selective cannabinoid receptor antagonist, primarily targeting the CB1 receptors found in the brain and peripheral tissues.

When ingested, Rimonabant binds to and blocks the CB1 receptors, preventing the activation of these receptors by endogenous cannabinoids such as anandamide. By blocking CB1 receptors, Rimonabant modulates the activity of the endocannabinoid system, which plays a role in various physiological processes, including appetite regulation, energy balance, and lipid metabolism.

Specifically, the blockade of CB1 receptors by Rimonabant affects the following:

Appetite Control

CB1 receptors are involved in the regulation of appetite and food intake. When CB1 receptors are activated, they stimulate the release of hunger-inducing neuropeptides and increase the rewarding properties of food. Rimonabant’s blockade of CB1 receptors reduces the activity of the endocannabinoid system, leading to decreased appetite and reduced food intake.

Energy Expenditure

The endocannabinoid system influences energy expenditure by regulating thermogenesis, the process by which the body produces heat and burns calories. By inhibiting CB1 receptors, Rimonabant may promote increased energy expenditure, contributing to weight loss.

Lipid Metabolism

CB1 receptor activation is associated with increased lipogenesis (fat storage) and decreased lipolysis (fat breakdown). Rimonabant’s antagonism of CB1 receptors may result in the suppression of lipogenesis and the promotion of lipolysis, potentially leading to a decrease in body fat accumulation.

It is important to note that while Rimonabant primarily acts as a CB1 receptor antagonist, it may also exhibit some additional effects or interactions with other receptors or systems in the body. The precise mechanisms and effects of Rimonabant may vary and are still a subject of ongoing research.

The mechanism of action of Rimonabant Powder is the same as that of Rimonabant in its other forms. Rimonabant Powder refers to the Powdered form of the drug Rimonabant, which is a selective cannabinoid receptor antagonist.

When Rimonabant Powder is administered, either orally or through formulation into various dosage forms, it undergoes dissolution and absorption in the body. Once absorbed, it interacts with the endocannabinoid system by targeting the CB1 receptors found in the brain and peripheral tissues.

What are the effects of Rimonabant?

Rimonabant, an anti-obesity medication, was initially developed to help individuals struggling with weight management. Its primary benefit was its ability to suppress appetite and promote weight loss. Specifically, Rimonabant was intended to be used for the following purposes:

Appetite Suppression

Rimonabant was designed to reduce appetite and promote weight loss by blocking the CB1 receptors in the brain involved in appetite regulation. By inhibiting these receptors, Rimonabant aimed to decrease feelings of hunger and cravings, helping individuals control their food intake.

Weight Loss

As a result of appetite suppression, Rimonabant was expected to lead to weight loss in individuals with obesity or overweight. Clinical trials showed that Rimonabant treatment could result in significant weight reduction when combined with a controlled diet and exercise.

Metabolic Improvements

Rimonabant exhibited potential benefits in improving metabolic parameters associated with obesity, such as lipid profiles, insulin resistance, and markers of cardiovascular risk. It aimed to promote positive changes in these metabolic factors, which are often compromised in individuals with excess weight.

Smoking Cessation Aid

Rimonabant was investigated for its potential use as an aid in smoking cessation. It was thought that by blocking the CB1 receptors, Rimonabant could reduce nicotine cravings and withdrawal symptoms, supporting individuals in their efforts to quit smoking.

Why does Rimonabant cause depression?

The exact mechanisms by which Rimonabant can lead to depression are not fully understood. However, studies and clinical reports have suggested a potential link between Rimonabant use and an increased risk of depression and other psychiatric side effects.

Rimonabant, as a selective cannabinoid receptor antagonist, blocks the activity of CB1 receptors in the endocannabinoid system.CB1 receptors play a role in various physiological processes, including mood regulation and emotional processing. By blocking CB1 receptors, Rimonabant may disrupt the normal functioning of the endocannabinoid system, which could contribute to changes in mood and mental well-being.

Additionally, the endocannabinoid system is involved in the regulation of stress responses and the modulation of neurotransmitters such as serotonin, which is known to play a crucial role in mood regulation. Disruption of these processes through CB1 receptor antagonism may potentially lead to depressive symptoms.

It is important to note that individual responses to medications can vary, and not everyone who takes Rimonabant will experience depression or related side effects. However, the occurrence of depression and other psychiatric symptoms associated with Rimonabant use led to the withdrawal of the drug from the market in several countries. So right now it may not be easy to buy Rimonabant Powder in the local pharmacy. If you want to buy Rimonabant Powder online, even though there are many Rimonabant Powder suppliers, you need to select the reliable one.

If you have concerns about depression or any other mental health-related issues, it is crucial to consult with a healthcare professional for proper evaluation and guidance.

Rimonabant withdrawal and ongoing research

Due to safety concerns, particularly psychiatric side effects, Rimonabant was eventually withdrawn from the market in several countries. However, the research and development of medications targeting the endocannabinoid system continue, with a focus on developing alternative compounds and therapies that address the limitations of Rimonabant.

Future research may involve refining the understanding of the endocannabinoid system, exploring potential applications of endocannabinoid modulation in various medical conditions, and developing safer and more effective medications in this field.

Where to buy Rimonabant Powder?

It is important to note even there are many Rimonabant Powder for sale online. It is not readily available for individual purchase or use. Rimonabant Powder is primarily utilized in research and development settings, including pharmaceutical companies and laboratories, for the purpose of studying the drug’s properties, conducting preclinical and clinical trials, and formulating new drug products. Due to safety concerns and potential side effects, it is important to buy high-quality Rimonabant Powder to avoid unnecessary side effects. How to select a reliable Rimonabant manufacturer, you need to check their independent HPLC and COA reports.AASRAW is a reliable supplier to trust. We supply good quality Rimonabant Powder. For wholesale orders of Rimonabant Powder, you will get a very competitive price.

Rimonabant Powder Testing Report-HNMR

What is HNMR and What does HNMR spectrum tell you? H Nuclear Magnetic Resonance (NMR) spectroscopy is an analytical chemistry technique used in quality control and research for determining the content and purity of a sample as well as its molecular structure. For example, NMR can quantitatively analyze mixtures containing known compounds. For unknown compounds, NMR can either be used to match against spectral libraries or to infer the basic structure directly. Once the basic structure is known, NMR can be used to determine molecular conformation in solution as well as studying physical properties at the molecular level such as conformational exchange, phase changes, solubility, and diffusion.

How to buy Rimonabant Powder from AASraw?

❶To contact us by our email inquiry system, or leave your WhatsApp number to us, our customer service representative(CSR) will contact you in 12 hours.

❷To provide us with your inquired quantity and address.

❸Our CSR will provide you with the quotation, payment term, tracking number, delivery ways, and estimated arrival date(ETA).

❹Payment done and the goods will be sent out in 12 hours.

❺Goods received and give comments.

Author of this article:
Dr. Monique Hong graduated from UK Imperial College London Faculty of Medicine

Scientific Journal paper Author:
1. Shira Hirsch
Obesity and Metabolism Laboratory, POB 12065, Jerusalem 9112001, Israel
2. Dalal AlKhelb
Center for Drug Discovery, Northeastern University, Boston, MA 02115, USA
3. Robert Ettaro
Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA
4. Alessandra Porcu
Department of Biomedical Sciences, University of Cagliari, 09042, Monserrato, Italy
In no way does this doctor/scientist endorse or advocate the purchase, sale, or use of this product for any reason. Aasraw has no affiliation or relationship, implied or otherwise, with this physician. The purpose of citing this doctor is to acknowledge and commend the exhaustive research and development work done by the scientists working on this substance.

References

[1] Soyka M.”Rimonabant and depression.”Pharmacopsychiatry.2008 Sep;41(5):204-5.doi: 10.1055/s-2008-1078744.Epub 2008 Sep 1.PMID: 18763226

[2] Boyd ST,Fremming BA.”Rimonabant–a selective CB1 antagonist.” Ann Pharmacother.2005 Apr;39(4):684-90.doi: 10.1345/aph.1E499.Epub 2005 Mar 8.PMID: 15755787

[3] Curioni C,André C.”Rimonabant for overweight or obesity.”Cochrane Database Syst Rev.2006 Oct 18;2006(4):CD006162.doi: 10.1002/14651858.CD006162.pub2.PMID: 17054276

[4] Wierzbicki AS.”Rimonabant: endocannabinoid inhibition for the metabolic syndrome.”Int J Clin Pract.2006 Dec;60(12):1697-706.doi: 10.1111/j.1742-1241.2006.01210.x.PMID: 17109677

[5] Cox SL.”Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors.”Drugs Today (Barc).2005 Aug;41(8):499-508.doi: 10.1358/dot.2005.41.8.893709.PMID: 16234873

[6] Bifulco M,Grimaldi C,Gazzerro P,Pisanti S,Santoro A.”Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.”Mol Pharmacol.2007 Jun;71(6):1445-56.doi: 10.1124/mol.106.033118.Epub 2007 Feb 27.PMID: 17327463

Get a Bulk quotation